



May 9, 2013

Company name: Dainippon Sumitomo Pharma Co., Ltd.  
Representative: Masayo Tada, President  
(Securities Codes: 4506, 1<sup>st</sup> Section of TSE and OSE)  
Contact: Atsuko Higuchi, Director, Corporate Communications  
(Phone: +81-6-6203-1407)

**Dainippon Sumitomo Pharma announces BBI608 Phase 1 Clinical Study Data to  
be presented at the 2013 ASCO Annual Meeting**

Osaka, Japan, May 9, 2013 – Dainippon Sumitomo Pharma Co., Ltd. (DSP) (Headquarters: Osaka, Japan; President: Masayo Tada) announces that an abstract was accepted for the presentation of efficacy and safety data from a Phase 1 study of “BBI608”, an anti-cancer treatment in development for adult patients with advanced malignancies, at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from May 31 to June 4, 2013.

Abstract Number: #2542  
Title: A Dose Escalation Phase 1 Study of a First-In-Class Cancer Stemness Inhibitor in Patients with Advanced Malignancies

The abstract will be publically released by ASCO on May 15, 2013 (Local Time).

(Reference)

BBI608 is an anti-cancer drug created and currently under development (Phase 3 in North America) by Boston Biomedical Inc. BBI608 has a novel mechanism that shows anti-tumor effects by targeting cancer stem cells (cancer cells with stem cell-like properties) as well as other heterogeneous cancer cells. By targeting cancer stem cells in addition to heterogeneous cancer cells, efficacy is expected in the current challenges in therapy against cancer, such as treatment resistance, metastasis and recurrence.